MSA
VNDA icon

Mason Street Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Mason Street Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,395
Closed -$268K – 1210
2020
Q4 		$268K Sell
20,395
-109
-0.5% -$1.31K ﹤0.01% 1353
2020
Q3 		$198K Buy
20,504
+140
+0.7% +$1.5K ﹤0.01% 1351
2020
Q2 		$233K Buy
20,364
+1,786
+10% +$20.2K ﹤0.01% 1298
2020
Q1 		$192K Hold
18,578
– – ﹤0.01% 1285
2019
Q4 		$305K Buy
18,578
+489
+3% +$7.39K 0.01% 1279
2019
Q3 		$240K Buy
18,089
+410
+2% +$5.71K ﹤0.01% 1322
2019
Q2 		$249K Buy
17,679
+772
+5% +$12.3K 0.01% 1303
2019
Q1 		$311K Buy
16,907
+619
+4% +$14.1K 0.01% 1286
2018
Q4 		$426K Buy
16,288
+811
+5% +$19.1K 0.01% 1088
2018
Q3 		$355K Buy
+15,477
New +$316K 0.01% 1215

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Mason Street Advisors's VNDA Position: Q1 2021 in Review

Mason Street Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2021, closing a stake of 20,395 shares — an estimated $268K sold.

Mason Street Advisors first reported a position in VNDA in Q3 2018 and held it in 10 quarters. The position peaked at $426K in Q4 2018. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

  • Mason Street Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 20,395 Vanda Pharmaceuticals shares in Q1 2021, an estimated $268K.
  • Mason Street Advisors first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Mason Street Advisors's Vanda Pharmaceuticals position peaked at $426K in Q4 2018.
  • 189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.